Palliative Care News

The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent high-dose chemotherapy and autologous stem cell transplantation, according to results of a randomized, phase 3 trial.

Patients with advanced cancer who were parents often based their decisions about aggressive cancer treatment and hospice care on the fact they had dependent children, according to results of a pilot study presented at the ASCO Quality Care Symposium.

Applying processes used in manufacturing to streamline patient flow can successfully reduce patient wait time and increase the confidence of residents at teaching hospitals, according to researchers at Johns Hopkins University.

The addition of chemotherapy to radiation therapy increased gastrointestinal toxicity but did not confer significant improvement in dysphagia or survival among patients with advanced esophageal cancer, according to results of a multinational, randomized phase 3 trial presented at the ASTRO Annual Meeting.

Patients with bone metastases who underwent single-fraction palliative radiation therapy reported similar improvements in pain, function and distress as those who underwent multiple-fraction radiation therapy, according to study results presented at the ASTRO Annual Meeting.

The implementation of a hospital-based palliative care program confers financial benefits to institutions and patients, particularly in cases of in-hospital mortality, according to recent findings.

A diagnosis of cancer is accompanied by a high degree of emotional stress.

About 25 million older Americans have been subjected to unwanted or excessive medical treatments, according to new survey data.

Black patients with cancer were more likely to receive morphine for pain, whereas non-Hispanic white patients were more likely to receive oxycodone, according to study results.

The anticonvulsant and analgesic agent gabapentin did not significantly improve delayed chemotherapy-induced nausea and vomiting compared with standard therapy, according to results of a phase 2, double blind, placebo-controlled study.